The relationship between ABO blood group and the risk of bleeding during vitamin K antagonist treatment [7]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 6, 2006, Pages 1418-1420

  Garcia, A A ^a   Van der Heijden, J F ^a   Meijers, J C M ^a   Rosendaal, F R ^b   Reitsma, Peter H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 8; PHENPROCOUMON; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD GROUP ABO SYSTEM; BLOOD SAMPLING; BRAIN HEMORRHAGE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; HEMARTHROSIS; HUMAN; INTRAOCULAR HEMORRHAGE; LETTER; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MUSCLE BLEEDING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM;

ABO BLOOD-GROUP SYSTEM; ANTICOAGULANTS; CASE-CONTROL STUDIES; FACTOR VIII; HEMORRHAGE; HUMANS; RISK FACTORS; VITAMIN K; VON WILLEBRAND FACTOR; WARFARIN;

EID: 33646778471     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01962.x     Document Type: Letter

References (11)

1. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153: 1557-62.
2. Reitsma PH, Heijden JF, Groot AP, Rosendaal FR, Buller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005; 2: E312.
3. van der Heijden JF, Rekke B, Hutten BA, van der Meer FJ, Remkes MG, Vermeulen M, Büller HR, Reitsma PH. Non-fatal major bleeding during treatment with vitamin K antagonists: Influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX. J Thromb Haemost 2004; 2: 1104-9.
4. Morelli VM, De Visser MC, Vos HL, Bertina RM, Rosendaal FR. ABO blood group genotypes and the risk of venous thrombosis: Effect of factor V Leiden. J Thromb Haemost 2005; 3: 183-5.
5. Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2005; 128: 100-7.
6. Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, Mateo J, Madoz P, Stone W, Blangero J, Fontcuberta J. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000; 20: 2024-8.
7. Olsson ML, Chester MA. A rapid and simple ABO genotype screening method using a novel B/O2 versus A/O2 discriminating nucleotide substitution at the ABO locus. Vox Sang 1995; 69: 242-7.
8. Olsson ML, Chester MA. Polymorphism and recombination events at the ABO locus: A major challenge for genomic ABO blood grouping strategies. Transfus Med 2001; 11: 295-313.
9. Yazer MH. What a difference 2 nucleotides make: A short review of ABO genetics. Transfus Med Rev 2005; 19: 200-9.
10. Yip SP. Sequence variation at the human ABO locus. Ann Hum Genet 2002; 66: 1-27.
11. Ruggeri ZM, Ware J. Willebrand factor. FASEB J 1993; 7: 308-16.